Wells Fargo
ABOS icon

Wells Fargo’s Acumen Pharmaceuticals ABOS Stock Holding History

Wells Fargo’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.9K Buy
10,108
+3,008
+42% +$7.67K ﹤0.01% 5706
2025
Q4 		$15K Buy
7,100
+600
+9% +$1.19K ﹤0.01% 5867
2025
Q3 		$11.1K Sell
6,500
-325
-5% -$450 ﹤0.01% 5925
2025
Q2 		$7.92K Sell
6,825
-20,853
-75% -$22.4K ﹤0.01% 6006
2025
Q1 		$30.4K Buy
27,678
+1,559
+6% +$2.23K ﹤0.01% 5562
2024
Q4 		$44.9K Buy
26,119
+4,861
+23% +$11.7K ﹤0.01% 5522
2024
Q3 		$52.7K Buy
21,258
+827
+4% +$2.24K ﹤0.01% 5327
2024
Q2 		$49.4K Buy
20,431
+19,223
+1,591% +$61.2K ﹤0.01% 5290
2024
Q1 		$4.89K Sell
1,208
-997
-45% -$3.76K ﹤0.01% 5894
2023
Q4 		$8.47K Buy
2,205
+2,011
+1,037% +$5.97K ﹤0.01% 5875
2023
Q3 		$805 Sell
194
-1,907
-91% -$11.8K ﹤0.01% 6248
2023
Q2 		$10.1K Sell
2,101
-995
-32% -$4.76K ﹤0.01% 5899
2023
Q1 		$12.6K Buy
3,096
+1,303
+73% +$6.8K ﹤0.01% 5785
2022
Q4 		$9.68K Sell
1,793
-297
-14% -$2K ﹤0.01% 5567
2022
Q3 		$21K Buy
2,090
+1,520
+267% +$8.72K ﹤0.01% 5361
2022
Q2 		$2K Sell
570
-2,203
-79% -$8.28K ﹤0.01% 6278
2022
Q1 		$11K Buy
2,773
+698
+34% +$3.8K ﹤0.01% 6224
2021
Q4 		$14K Buy
2,075
+2,024
+3,969% +$22.2K ﹤0.01% 6431
2021
Q3 		$1K Buy
+51
New +$849 ﹤0.01% 6639

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Wells Fargo's ABOS Position: Q1 2026 in Review

Wells Fargo increased its Acumen Pharmaceuticals (ABOS) stake by 42% in Q1 2026, buying an estimated $7.67K and bringing the position to 10,108 shares worth $23.9K. The position accounts for ﹤0.01% of the portfolio, ranked #5706.

Wells Fargo first reported a position in ABOS in Q3 2021 and has held it in 19 quarters since. The position peaked at $52.7K in Q3 2024. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Wells Fargo held 10,108 shares of Acumen Pharmaceuticals worth $23.9K as of Q1 2026.
  • Wells Fargo bought 3,008 Acumen Pharmaceuticals shares in Q1 2026, an estimated $7.67K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5706 holding.
  • Wells Fargo first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • Wells Fargo's Acumen Pharmaceuticals position peaked at $52.7K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.